Hara K, et al. - In this propensity score analysis, researchers compared the efficacy of radiotherapy vs radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC). For this investigation, they reviewed consecutive subjects with ≤3 early-stage HCC lesions and tumor diameters ≤3 cm treated with RFA or radiotherapy. Between 2012 and 2016, a total of 231 patients were eligible for RFA and radiotherapy, respectively, with 474 tumors and 143 patients with 221 tumors. According to findings, radiotherapy has excellent local control and comparable overall survival in well-compensated liver function patients, showing beneficial features and offsetting deficiencies in other treatments. For patients who are not RFA candidates, radiotherapy seems to be a satisfactory alternate treatment option.